Buechner, T. and Hiddemann, W. and Woermann, B. and Loeffler, H. and Ludwig, W. D. and Schoch, C. and Haferlach, T. and Maschmeyer, G. and Staib, P. and Aul, C. and Heyll, A. and Grueneisen, A. and Rasche, H. and Eimermacher, H. and Balleisen, L. and Pielken, H. J. and Reis, H. E. and Griesinger, F. and Reichle, A. and Sauerland, M. C. and Heinecke, A. (2000) Acute myeloid leukemia in adults: Is postconsolidation maintenance therapy necessary? INTERNATIONAL JOURNAL OF HEMATOLOGY, 72 (3). pp. 285-289. ISSN 0925-5710, 1865-3774
Full text not available from this repository. (Request a copy)Abstract
Maintenance treatment for patients with acute myeloid leukemia (AML) in I-emission has recently been controversially discussed and even abandoned by several groups. An analysis of 14 recently published multicenter trials, however, revealed the highest probabilities of relapse-free survival (RFS), in the range of 35% to 42% at 4 to 5 years, only in patients assigned to maintenance treatment as far as adult age and intent-to-treat conditions were considered. After having demonstrated a superior RFS rate from 3 years of maintenance after standard-dose consolidation compared with that from consolidation alone (P = .00004), the German AMLCG requestioned the effect of maintenance randomly compared with sequential high-dose cytosine arabinoside (Ara-C) and mitoxantrone in patients who received intensified induction treatment. The results show an advantage for maintenance treatment (RFS rate of 32%) versus the sequential Ara-C and mitoxantrone treatment (RFS rate of 25%) (P = .021). We conclude that maintenance treatment continues to substantially contribute to the management of adult patients with AML, even as part of recent strategies using intensified induction treatment, and thus appears necessary in these settings. Int J Hematol. 2000;72:285-289. (C) 2000 The Japanese Society of Hematology.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BONE-MARROW TRANSPLANTATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; DOSE CYTOSINE-ARABINOSIDE; AML COOPERATIVE GROUP; GROUP-B; INTENSIFICATION THERAPY; INTENSIVE CHEMOTHERAPY; FIRST REMISSION; INDUCTION; acute myeloid leukemia; postremission therapy; maintenance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Mar 2022 14:31 |
| Last Modified: | 22 Mar 2022 14:31 |
| URI: | https://pred.uni-regensburg.de/id/eprint/42172 |
Actions (login required)
 |
View Item |
